TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06203210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: 12 mg/kg intravenous dose on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered per local SoC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrubicin
Description: Amrubicin will be administered per local SoC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: Lurbinectedin will be administered per local SoC
Study: NCT06003166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminopyridine
Description: Study drug will be a one time dose of 5mg immediate release 4 aminopyridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-Aminopyridine
Description: Study drug will be a one time dose of 5mg immediate release 4 aminopyridine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT06252714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defecation Posture Modification Device
Description: Patients will be asked to use the defecation posture modification device with each bowel movement for two weeks.
Study: NCT05525741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non segmental vitiligo
Description: The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.

Intervention type: OTHER
Group type: OTHER
Intervention: Health Volunteers
Description: The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.
Study: NCT06259357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized protective mechanical ventilation in prone position
Description: Prone Position: Study subjects randomized to the intervention group will be placed and maintained in prone position for at least 16 hours/day until the time of organ procurement or decline (typically 24-48 hours after donation consent) or the time that the lungs are declined for transplant.
Study: NCT05160545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-035
Description: Administration by intravenous infusion
Study: NCT05473507

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Dermoscopy
Description: Digital Dermoscopy will be performed every 3 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Reflectance confocal microscopy (RCM)
Description: Reflectance confocal microscopy (RCM) will be performed every 3 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Optical coherence tomography (OCT) will be performed every 3 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermtech tape-stripping
Description: Dermtech tape-stripping for genetic analysiswill be performed every 6 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Skin Examinations
Description: Total Skin Examinations will be performed every 12 months.
Study: NCT06556485

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Preventive ablation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Optimal medical therapy
Study: NCT05015504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
Study: NCT06278051

Intervention type: DRUG
Intervention: Rivaroxaban granules for oral suspension
Description: Treatment dose and period decided by its prescription

Intervention type: DRUG
Intervention: Warfarin
Description: Treatment dose and period decided by its prescription
Study: NCT05071729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Single oral dose of elinzanetant on Day 1.
Study: NCT05570045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colos Gain
Description: Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks.
Study: NCT05651893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: re-examination
Description: During colonoscopy, the left colon was examined a second time in the forward view.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: extended withdraw time
Description: During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
Study: NCT06410079

Intervention type: PROCEDURE
Intervention: total hip replacement
Description: Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene

Intervention type: PROCEDURE
Intervention: total hip replacement
Description: Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene
Study: NCT06149819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic and safety of a nursing pathway for the management of non-traumatic chest pain
Description: trained nurses will take in charge non-traumatic chest pain patient according to the standardized algorithm based on the recommendations .
Study: NCT04785391

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine collection for NEPHROCLEAR CCL14 Test
Description: Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
Study: NCT04810520

Intervention type: OTHER
Intervention: Point-of-care ultrasound with tele-supervision
Description: Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.

Intervention type: OTHER
Intervention: Point-of-care ultrasound without tele-supervision
Description: Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
Study: NCT04647669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: 200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: 100 mg capsules twice daily every 12 h for 10 days taken with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Treatment according to local hospital protocol
Study: NCT05383911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCD Shared Decision-Making Toolkit for AYAs - including VR
Description: The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including virtual reality, online (videos, animations, articles), and print materials); and 3) implementation (e.g., clinic audit and feedback strategies).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCD Shared Decision-Making Toolkit for AYAs - without VR
Description: The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including online videos, animations, and articles as well as print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
Study: NCT06473051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Original set
Description: The original set of implementation strategies will include the same strategies as applied in the INTERCARE study by the research group but will be updated to fit the current practice field.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted set
Description: The adapted set of implementation strategies will contain similar implementation strategies that are expected to achieve the same outcomes as the first set, but with less resources required (for instance, by providing group coaching sessions rather than single sessions).
Study: NCT05772520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: oral tablets administered 20 mg BID and 40 mg BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: oral tablets administered 20 mg BID and 40 mg BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
Study: NCT06046248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: 200mg PO QD x 24 cycles (28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
Study: NCT03954431

Intervention type: DIAGNOSTIC_TEST
Intervention: Dedicated breast CT(BCT)
Description: The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
Study: NCT05444881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention (Headspace TM)
Description: A commercially available mindfulness mobile phone application (HeadspaceTM) will be used. The use of HeadspaceTM in the current protocol is approved by NYSPI Information Technology Services.~An mHealth mindfulness program such as Headspace provides self-paced, guided mindfulness meditations through a website or mobile app (iOS and Android). The program consists of basic meditation courses as well as courses targeting stress management, anxiety, depression, and parenting. Based on the qualitative interviews with parents in Phase I, psychoeducation will be included on mindfulness practice and mental health, emphasizing basic meditation courses, and asking parents to complete daily assignments of 10 to 20 min a day during the 6-week period. As an engagement strategy, every week participants in the intervention group will receive a call or an email or text message (depends on preference; partisans may opt out to receive email/text messages).
Study: NCT05225103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFETY-Acute intervention
Description: The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
Study: NCT05401838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Brief Cognitive-Behavioral Therapy (G-BCBT)
Description: G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dialectical Behavior Therapy (DBT) Skills Group
Description: DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
Study: NCT06163326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 50 mg capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 50 mg capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 100 mg
Description: Ritlecitinib 100 mg capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 100 mg
Description: Ritlecitinib 100 mg capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsule once daily
Study: NCT05504707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 - primed Dendritic cells
Description: Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER2 - primed Dendritic cells dose 10-20 million Dose level 2: HER2 - primed Dendritic cells dose 30-50 million Dose level 3: HER2 - primed Dendritic cells dose 80-100 million

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER3 - primed Dendritic cells
Description: Dendritic cell will be administered at ultra-sound guided injections. Participants will receive 8 intratumoral injections. These injections will be administered twice per week per week (given 3 days apart). Participants will receive alternating injections (3 days apart) of HER2-primed followed by HER3-primed DCs.~Participants will be treated at the following dose levels:~Dose level 1: HER3 - primed Dendritic cells dose 10-20 million Dose level 2: HER3 - primed Dendritic cells dose 30-50 million Dose level 3: HER3 - primed Dendritic cells dose 80-100 million
Study: NCT06073704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antimicrobial photodynamic therapy (aPDT)
Description: Scaling and root planing followed by antimicrobial photodynamic therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment of scaling and root planing
Study: NCT04979598

Intervention type: OTHER
Intervention: Home exercise program
Description: A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
Study: NCT06141083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI188 Probiotic
Description: take two tablets per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take two tablets per day
Study: NCT00828685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRPP
Description: Closed reduction, percutaneous pinning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF
Description: Open reduction, internal fixation
Study: NCT05899712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Removable Partial Denture Construction
Description: Construction of class I Removable partial denture by digital workflow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Removable Partial Denture Construction
Description: Construction of class I Removable partial denture by digital workflow
Study: NCT05553626

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left bundle branch pacing
Description: Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Description: Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT/CRTD device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-ventricular pacing
Description: Bi-ventricular pacing by a CRT/CRTD device
Study: NCT05789771

Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)

Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)

Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib 200 mg orally every 12 hours
Study: NCT04564326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve Group block
Description: Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
Study: NCT05143151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD276 CAR-T cells
Description: CD276 CAR-T cells infusion
Study: NCT04867902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology-Motivational Interviewing Intervention
Description: Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
Study: NCT04564326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facia Iliaca block
Description: Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
Study: NCT06419647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Daily mood tracking tasks
Study: NCT05907473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: Patients in this group will play balance-based games with the Virtual Reality System.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Description: In the conventional rehabilitation program, bed exercises, mat activities, balance exercises inside or outside the parallel bar and walking training will be given to the patients every weekday.